Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
September 30, 2026 -5.749M
June 30, 2026 -9.646M
March 31, 2026 -9.001M
December 31, 2025 -6.371M
September 30, 2025 -5.569M
June 30, 2025 -8.009M
March 31, 2025 -7.252M
December 31, 2024 -9.26M
September 30, 2024 -5.936M
June 30, 2024 -11.14M
March 31, 2024 -13.23M
December 31, 2023 -10.19M
September 30, 2023 -8.181M
June 30, 2023 -7.868M
March 31, 2023 -12.20M
December 31, 2022 -12.27M
September 30, 2022 -13.12M
June 30, 2022 -12.13M
March 31, 2022 -16.82M
December 31, 2021 -8.171M
September 30, 2021 -9.61M
June 30, 2021 -6.659M
March 31, 2021 -13.18M
December 31, 2020 -5.715M
September 30, 2020 -5.877M
Date Value
June 30, 2020 -5.131M
March 31, 2020 -9.016M
December 31, 2019 -5.599M
September 30, 2019 -7.882M
June 30, 2019 -2.12M
March 31, 2019 -10.60M
December 31, 2018 -4.94M
September 30, 2018 -8.223M
June 30, 2018 -6.938M
March 31, 2018 -9.964M
December 31, 2017 -7.505M
September 30, 2017 -16.48M
June 30, 2017 -9.223M
March 31, 2017 -15.15M
December 31, 2016 -9.387M
September 30, 2016 -7.583M
June 30, 2016 -10.85M
March 31, 2016 -7.987M
December 31, 2015 -10.86M
September 30, 2015 -4.482M
June 30, 2015 -6.786M
March 31, 2015 -7.759M
December 31, 2014 -4.692M
September 30, 2014 -2.085M
June 30, 2014 -4.730M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. -5.62M
Agenus, Inc. -20.10M
Amgen, Inc. 4.241B
Anika Therapeutics, Inc. 8.377M
BioCryst Pharmaceuticals, Inc. 32.69M